SCALE co-director Michael Gold, MD, discusses the breadth of offerings at the meeting, which spans medical dermatology, practice management, and aesthetics. “We do this to teach,” he says.
Learning From the Best and Brightest
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
SCALE co-director Michael Gold, MD, discusses the breadth of offerings at the meeting, which spans medical dermatology, practice management, and aesthetics. “We do this to teach,” he says.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
NYHA FC and Finerenone Response: Clinical Trial Insights
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?